Phase 3 Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with schizophrenia as their primary condition
- People who are currently experiencing a worsening or return of symptoms serious enough to require a hospital stay
- People who are willing and able to stay in a hospital setting for the full duration of the study and follow the study's requirements
- People who are able to stop taking certain medications, including antipsychotics, before the study begins
Who may not be able to join:
- People who have a known allergic reaction or sensitivity to any ingredient in the study drug NBI-1117568
- People who have an unstable or poorly managed ongoing medical condition or chronic illness
- People who the trial doctor considers to be at immediate risk of harming themselves or others
- People who have been diagnosed with a moderate or severe substance use problem (not including nicotine or caffeine) within the 6 months before screening
- People whose alcohol or drug test comes back positive for substances that are not permitted in the study
- People who have a history of not following study rules in past research, or who the trial doctor believes would have difficulty sticking to the study requirements
Important: Always verify eligibility with the trial site directly before applying.
Note: There may be additional criteria beyond those listed here that the trial site will assess.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Development Lead, Neurocrine Biosciences
Phone: 877-641-3461
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.